onartuzumab + cobimetinib

Onartuzumab + cobimetinib is an experimental combination regimen under clinical investigation for the treatment of advanced solid tumors. **Onartuzumab** is a monovalent monoclonal antibody that targets the MET receptor (hepatocyte growth factor receptor), inhibiting MET-driven signaling pathways implicated in tumor growth and progression. **Cobimetinib** is a small molecule inhibitor that selectively targets MEK1 and MEK2, key components of the MAPK/ERK pathway, to block the downstream signaling often activated by oncogenic mutations in RAS or BRAF. The rationale for this combination is to simultaneously interrupt two complementary pro-oncogenic signaling routes: the MET pathway (through onartuzumab) and the MAPK pathway (through cobimetinib), potentially improving efficacy in cancers, especially those showing resistance to monotherapy approaches. Clinical development for this combination includes studies in solid tumors; however, as of the latest available data, the combination has not advanced to late-stage trials or received regulatory approval[1][4].